Sears et al. reported that panobinostat and vorinostat, both pan-HDAC inhibitors, were more effective in treating IDH-mutant patient-derived glioma cell lines than the corresponding IDH wild-type lines [32]. The gene discussed is IDH2; the disease is central nervous system cancer.